Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice.
We studied the combination of amphotericin B lipid complex (ABLC) and caspofungin in mice with disseminated Rhizopus oryzae. Combination therapy improved survival compared to that of mice given monotherapy and that of untreated controls (P < 0.05) but did not improve organ clearance. In addition, prophylactic combination therapy was not more effective than prophylactic ABLC alone.
Spellberg
Brad
B
Division of Infectious Diseases, Harbor-UCLA Research and Education Institute, St. John's Cardiovascular Research Center, 1124 West Carson St., Torrance, CA 90502, USA.
Fu
Yue
Y
Edwards
John E
JE
Ibrahim
Ashraf S
AS
D000666:Amphotericin B / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D000077336:Caspofungin; D003921:Diabetes Mellitus, Experimental / Q000382:microbiology / Q000473:pathology; D016883:Diabetic Ketoacidosis / Q000150:complications* / Q000378:metabolism; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009091:Mucormycosis / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010713:Phosphatidylcholines / Q000627:therapeutic use*; D010715:Phosphatidylglycerols / Q000627:therapeutic use*; D012233:Rhizopus; D013534:Survival
D000935:Antifungal Agents; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin